VVUS - VIVUSAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $0.47 | Open | |
| Volume | Market Cap | 8.34M | |
| Yield | Last Dividend |
| Bankrupt Drugmaker Vivus Gets Approval t... | 07/08/20 |
| Vivus, which filed for bankruptcy with plans to be acquired by Carl Icahn???s investment firm, received interim court approval to preserve $648 millio... | |
| The Daily Biotech Pulse: Intersect ENT J... | 07/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbV... | |
| VIVUS Reports First Quarter 2020 Financi... | 05/06/20 |
| Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the ???Company???), ... | |
| VIVUS Announces Agreement with IEH Bioph... | 05/01/20 |
| CAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the ???Company???), a biopharmaceutical company, today announced an agre... | |
| Vivus Shares Rally On Accelerated Teleme... | 03/31/20 |
| Shares of biopharma company VIVUS, Inc. (NASDAQ: VVUS ) are skyrocketing following an announcement concerning launch plans for telemedicine services. ... | |
| The Daily Biotech Pulse: Takeda Jumps In... | 03/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) ... | |
| The Daily Biotech Pulse: Gilead Kicks Of... | 02/27/20 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs o... | |
| The Daily Biotech Pulse: Sanofi Reports ... | 01/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) ... | |
| The Daily Biotech Pulse: Novartis Earnin... | 01/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) ... | |
| VIVUS to Present at Piper Jaffray 31st A... | 11/25/19 |
| CAMPBELL, Calif., Nov. 25, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) (the ???Company???), a biopharmaceutical company, today announced that John Amos, Chief ... | |
| Vivus shares rise on bulimia data for Qs... | 11/20/19 |
| Shares of Vivus Inc. rose 9% in morning trading after the drugmaker said its weight-loss drug Qsymia can reduce binging frequency for patients with bi... | |
| VIVUS Reports Third Quarter 2019 Financi... | 11/05/19 |
| CAMPBELL, Calif., Nov. 05, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the ???Company???), a specialty pharmaceutical company committed to the development and... | |
| VVUS: Debt Reduced by ~$50 Million | 10/07/19 |
| By John Vandermosten, CFA NASDAQ:VVUS Vivus, Inc. (NASDAQ:VVUS) announced the pay down of $48.6 million of its senior secured notes due 2024. The secu... | |
| VIVUS Announces Acceptance of Qsymia Dec... | 10/07/19 |
| VIVUS, Inc. (VVUS) (the ???Company???), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Ic... | |
| VIVUS' Qsymia now approved in Korea | 08/05/19 |
| VIVUS (VVUS) announces that its Korean marketing partner, Alvogen, has obtained marketing approval for Qsymia (phentermine and topiramate extended-rel... | |
| VIVUS Announces Approval of Qsymia?? in ... | 08/05/19 |
| VIVUS receives $2.5 million milestone payment CAMPBELL, Calif., Aug. 05, 2019 -- VIVUS, Inc. (Nasdaq:VVUS) (the ???Company???), a biopharmaceutical co... | |
| VIVUS Initiates Phase Four Safety and Ef... | 05/28/19 |
| -Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical n... | |
| VIVUS, Inc. (VVUS) CEO John Amos on Q1 2... | 04/30/19 |
| VIVUS, Inc. (NASDAQ:VVUS) Q1 2019 Earnings Conference Call April 30, 2019 04:30 PM ET Company Participants David Carey - Managing Director, Investor R... | |
| Vivus beats by $0.42 | 04/30/19 |
| No summary available. | |
| NEW, TIGR, IONS and EHTH among notable m... | 04/17/19 |
| No summary available. | |
| Vivus up 11% on new VA contract | 04/17/19 |
| No summary available. | |
| Vivus beats by $0.11, beats on revenue | 02/26/19 |
| No summary available. | |
| Positive And Negative Forensic Value Sto... | 02/04/19 |
| No summary available. | |
| Microbot Medical leads healthcare gainer... | 01/14/19 |
| No summary available. | |
| Microbot Medical leads healthcare gainer... | 01/14/19 |
| No summary available. | |
| Vivus up 6% premarket on published Qsymi... | 01/14/19 |
| No summary available. | |
| Vivus up 6% premarket on published Qsymi... | 01/14/19 |
| No summary available. | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swing Trading Cheap Stocks <~ $10 | Michael S. DeVries | 65.00 % | Follow |
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
